Antihyperglycemic activity with DPP-IV inhibition of alkaloids from seed extract of Castanospermum australe: Investigation by experimental validation and molecular docking

Phytomedicine

Volumn 20, Issue 1, 2012, Pages 24-31

  Bharti, Sudhanshu Kumar ^a   Krishnan, Supriya ^b   Kumar, Amit ^c   Rajak, Kaushal Kishore ^d   Murari, Krishna ^e   Bharti, Binod Kumar ^e   Gupta, Ashok Kumar ^a,f  

^a PATNA UNIVERSITY   (India)

^b MAGADH UNIVERSITY   (India)

^c JAWAHARLAL NEHRU UNIVERSITY   (India)

^d INDIAN VETERINARY RESEARCH INSTITUTE   (India)

^e BIHAR AGRICULTURAL UNIVERSITY   (India)

^f National Institute of Pharmaceutical Education and Research (NIPER)   (India)

Author keywords

DPP IV inhibitor; Glucose tolerance; Hyperglycemia; Insulin resistance; Type 2 diabetes

Indexed keywords

7 DEOXY 6 EPI CASTANOSPERMINE; AUSTRALINE; BERBERINE; CASTANOSPERMINE DERIVATIVE; CASTANOSPERMUM AUSTRALE EXTRACT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIPROTIN A; GLUCOSE; GLUCOSIDASE; HEMOGLOBIN A1C; INSULIN; PLANT EXTRACT; UNCLASSIFIED DRUG;

ANTIDIABETIC ACTIVITY; ARTICLE; CASTANOSPERMUM; DRUG INHIBITION; HEMOGLOBIN BLOOD LEVEL; HYPERGLYCEMIA; IC 50; INSULIN BLOOD LEVEL; MOLECULAR DOCKING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLANT SEED; PRIORITY JOURNAL; RAT;

ALKALOIDS; ANIMALS; BERBERINE; BLOOD GLUCOSE; CASTANOSPERMUM; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCOSE INTOLERANCE; HEMOGLOBIN A, GLYCOSYLATED; HYPOGLYCEMIC AGENTS; INDOLIZINES; INSULIN; INSULIN RESISTANCE; MOLECULAR DOCKING SIMULATION; PHYTOTHERAPY; PLANT EXTRACTS; POLOXAMER; RATS; RATS, WISTAR; SEEDS;

ANIMALIA; CASTANOSPERMUM AUSTRALE; RATTUS;

EID: 84870415970     PISSN: 09447113     EISSN: 1618095X     Source Type: Journal    
DOI: 10.1016/j.phymed.2012.09.009     Document Type: Article

References (66)

1. V.U. Ahmed, W. Ahmed, and K. Usmanghani Triterpenoidsaponins from leaves of Castanospermum australe Phytochemistry 31 8 1992 2805 2807
2. W. Ahmed, U.G. Khan, I. Ahmed, V.U. Ahmed, and T. Miyase Isolation and characterization of saponins from Castanospermum australe Cunn. et Fraser Chemical & Pharmaceutical Bulletin (Tokyo) 42 2 1994 314 317 (Pubitemid 24119650)
3. K.G.M.M. Alberti, and C.M. Press The biochemistry and the complication of diabetes H. Keen, J. Javve, Complications of Diabetes vol. 2 1982 Edward Arnold Publishers London 31 70
4. S.I. Ali Flora of Pakistan E. Nasir, S.I. Ali, Papilionaceae 1977 Fakhri Printing Press Karachi 30
5. I.M. Al masri, M.K. Mohammad, and M.O. Tahaa Inhibition of dipeptidyl peptidase IV (DPP-IV) is one of the mechanisms explaining the hypoglycemic effect of berberine Journal of Enzyme Inhibition and Medicinal Chemistry 24 2009 1061 1066
6. R.F. Alponti, R. Frezzatti, J.M. Barone, S. Alegre Vde, and P.F. Silveiraa Dipeptidyl peptidase IV in the hypothalamus and hippocampus of monosodium glutamate obese and food-deprived rats Metabolism 60 2 2011 234 242
7. D.J. Augeri, J.A. Robl, D.A. Betebenner, D.R. Magnin, A. Khanna, and J.G. Robertson Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of Type 2 diabetes Journal of Medicinal Chemistry 48 2005 5025 5037 (Pubitemid 41033142)
8. E. Bonora, ZavaraiI, C. Coscelli, and U. Butturini Decreased hepatic insulin excretion subjects with mild glucose intolerance Metabolism 32 1983 438 444
9. E. Bonora, F. Saggiani, and G. Targher Homeostasis model assessment closely mirrors glucose clamp technique in the assessment of insulin sensitivity Diabetes Care 23 2000 57 63
10. D. Braham, and P. Trinder An improved colour reaction for the determination of blood glucose by oxidase system Analyst 1972 142 144
11. P. Bannon Effect of pH on the elimination of labile fraction of glycosylated hemoglobin Clinical Chemistry 28 1982 21 83
12. A.D. Bolzan, and M.S. Bianchi Genotoxicity of streptozotocin Mutation Research 512 2002 121 134 (Pubitemid 35441051)
13. R.N. Chopra, S.L. Nayar, and I.C. Chopra Glossary of Indian Medicinal Plants 1956 Council of Scientific and Industrial Research New Delhi p. 55
14. P. Cole, N. Serradell, R. Bolos, and R. Castaner Saxagliptin Drugs Future 33 2008 577 586
15. J.D. Croxtall, and S.J. Keam Vildagliptin: a review of its use in the management of type 2 diabetes mellitus Drugs 68 2008 2387 2409
16. C.F. Deacon, A.H. Johnsen, and J.J. Holst Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide which is a major endogenous metabolite in vivo Journal of Endocrinology and Metabolism 80 1995 952 957
17. C.F. Deacon Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes Current Opinion in Investigational Drugs 9 2008 402 413 (Pubitemid 351507666)
18. H.U. Demuth, C.H. McIntosh, and R.A. Pederson Type 2 diabetes - therapy with dipeptidyl peptidase IV inhibitors Biochimicaet Biophysica Acta 1751 2005 3 44
19. 5, from Castanospermum australe Cunnet Fras, Austral Australian Journal of Chemistry 16 5 1963 900 905
20. H.C. Fehmann, and J.F. Habener Insulinotropic hormone glucagon-like peptide-I (7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells Endocrinology 130 1992 159 166
21. B. Gallwitz Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes IDrugs 11 2008 906 917
22. M.H. Giroix, B. Portha, M. Kergoat, D. Bailbe, and L. Picon Glucose insensitivity and amino-acid hypersensitivity of insulin release in rats with non-insulin dependent diabetes: a study with the perfused pancreas Diabetes 32 1983 445 451 (Pubitemid 13129965)
23. D.E. Goldstein How much do you know about glycated hemoglobin testing Clinical Diabetes July-August 1995 60 63
24. B.J. Goldstein Insulin resistance as the core defect in type 2 diabetes mellitus American Journal of Cardiology 90 2002 3G 10G (Pubitemid 35266675)
25. L. Groop Genetics of the metabolic syndrome British Journal of Nutrition 83 2000 S39 S48
26. S. Henness, and S.J. Keam Vildagliptin Drugs 66 2006 1989 2001 (Pubitemid 44771935)
27. L.D. Hohenchutz, E.A. Bell, P.J. Jewess, D.P. Leworthy, R.J. Pryce, E. Arnold, and J. Clardy Castanospermine, A 1,6,7,8-tetrahydroxyoctahydroindolizine alkaloid, from seeds of Castanospermum australe Phytochemistry 20 4 1981 811 814
28. R.R. Holman, and R.C. Turner Oral agents and insulin in the treatment of NIDDM J. Pickup, G. Williams, Textbook of Diabetes 1991 Blackwell Oxford, UK 407 469
29. G. Jones, P. Willett, R.C. Glen, A.R. Leach, and R. Taylor Development and validation of a genetic algorithm for flexible docking Journal of Molecular Biology 267 1997 727 748 (Pubitemid 27170693)
30. D. Kim, L. Wang, M. Beconi, G.J. Eiermann, M.H. Fisher, and H. He (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl]-1-(2,4,5-trifluorophenyl) butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes Journal of Medicinal Chemistry 48 2005 141 151 (Pubitemid 40105255)
31. A.M. Lambeir, C. Durinx, S. Scharpé, and I. De Meester Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV Critical Reviews in Clinical Laboratory Sciences 40 2003 209 294 (Pubitemid 36775376)
32. A.M. Lambier, S. Scharpe, and I. De Meester DPP4 inhibitor for diabetes - what next? Biochemical Pharmacology 76 2008 1637 1643
33. J. Larner Insulin and oral hypoglycemic drugs: glucagon A.G. Gilman, L.S. Goodman, T.W. Rall, F. Murad, The Pharmacological Basis of Therapeutics 7th ed. 1985 Macmillan New York 149 151
34. T. Lubbers, M. Boehringer, L. Gobbi, M. Hennig, D. Hunziker, B. Kuhn, B. Loeffler, P. Mattei, R. Narquizian, J. Peters, Y. Ruff, H.P. Wessel, and P. Wyss 1,3-Disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizinedipeptidyl peptidase IV inhibitors Bioorganic and Medicinal Chemistry Letters 17 11 2007 2966 2970 (Pubitemid 46702649)
35. K.A. Lyseng-Williamson Sitagliptin Drugs 67 2007 587 597 (Pubitemid 46440314)
36. T.J. Kieffer, and J.F. Habener The glucagon-like peptides Endocrine Reviews 20 1999 876 913 (Pubitemid 30647076)
37. F.E. Koehn, and G.T. Carter The evolving role of natural products in drug discovery Nature Reviews Drug Discovery 4 2005 206 220 (Pubitemid 40372555)
38. R. Lautamaki, R. Borra, P. Iozzo, M. Komu, T. Lehtimaki, M. Salmi, S. Jalkanen, K.E. Airaksinen, J. Knuuti, R. Parkkola, and P. Nuutila Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes American Journal of Physiology - Endocrinology and Metabolism 291 2006 E282 E290
39. M.B. Maes, V. Dubois, I. Brandt, A.M. Lambeir, P. Van der Veken, K. Augustyns, J.D. Cheng, X. Chen, S. Scharpe, and I. De Meester Dieptidyl peptidase 8/9 like activity in human leukocytes Journal of Leukocyte Biology 81 5 2007 1252 1257 (Pubitemid 46702044)
40. R. Mentlein, B. Gallwitz, and W.E. Schmidt Dipeptidyl peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, peptide histidine-methionine and is responsible for their degradation in human serum European Journal of Biochemistry 214 1993 829 835 (Pubitemid 23188160)
41. R.J. Molyneux, M. Benson, R.Y. Wong, J.E. Tropea, A.D. Elbein, and Australine A novel pyrolizidine alkaloid glucosidase inhibitor from Castanospermum australe Journal of Natural Products 51 6 1988 1198 1206 (Pubitemid 19026545)
42. B. Murali, U.M. Upadhyaya, and R.K. Goyal Effect of chronic treatment with Enicostemmalittorale in non-insulin dependent diabetic rats Journal of Ethnopharmacology 81 2002 199 204 (Pubitemid 34628502)
43. R.J. Nash, S.V. Evans, L.E. Fellows, and E.A. Bell A.A. Seawright, M.P. Hegarty, L.F. James, R.F. Keeler, Plant Toxicology 1985 Dominion Press Hedges and Bell Melbourne 309 314
44. M.A. Nauck, U. Niedereichholz, R. Ettler, J.J. Holst, C. Orskov, and R. Ritzel Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans American Journal of Physiology 273 1997 E981 E988
45. NPS - better medicines, better health, 2010. Vildagliptin for type 2 diabetes. http://www.nps.org.au/consumers/publications/medicine-update/issues/ vildagliptin.
46. E.A. Nyenwe, T.W. Jerkins, G.E. Umpierrez, and A.E. Kitabchi Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes Metabolism: Clinical and Experimental 60 2011 1 23
47. C. Orwa, A. Mutua, R. Kindt, R. Jamnadass, and S. Anthony Agroforestree Database: A Tree Reference and Selection Guide Version 4.0 2009 World Agroforestry Centre Kenya
48. L. Pari, and G. Saravanan Antidiabetic effect of Cogentdb, a herbal drug in alloxan-induced diabetes mellitus Comparative Biochemistry and Physiology-Part C 131 2002 19 25 (Pubitemid 34131573)
49. B. Portha, L. Picon, and G. Rosselin Chemical diabetes in the adult rats as the spontaneous evolution of neonatal diabetes Diabetologia 17 1979 371 377 (Pubitemid 10219170)
50. R.E. Pratley Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes Expert Opinion on Pharmacotherapy 10 2009 503 512
51. K. Rao, R. Giri, M.M. Kesavulu, and C. Apparao Herbal medicine in the management of diabetes mellitus Manphar Vaidhya Patrica 1 1997 33 35
52. M.G. Rao, L.R. Row, and C. Rukmini Chemistry of saponins Part IV, A new triterpenesapogenin, Castenogenol from the bark of Castanospermum australe Cunn. Fras Indian Journal of Chemistry 7 12 1969 1203 1205
53. R.P. Robertson, and J.S. Harmon Diabetes, glucose toxicity, and oxidative stress: a case of double jeopardy for the pancreatic islet β-cell Free Radical Biology and Medicine 41 2006 177 184 (Pubitemid 43928495)
54. J. Rungby Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes Expert Opinion on Investigational Drugs 18 2009 835 838
55. T. Szkudelski The mechanism of alloxan and streptozotocin action in β-cells of the rat pancreas Physiological Research 50 2001 537 546 (Pubitemid 34087272)
56. A. Tenenbaum, E.Z. Fisman, and M. Motro Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptor (PPAR) Cardiovascular Diabetology 2 2003 4
57. A. Tiwari Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes Current Opinion in Investigational Drugs 10 2009 1091 1104
58. T. Uno, I. Ohsawa, M. Tokudome, and U. Sato Effect of Goshajinkigan on insulin resistance in patients with type 2 diabetes Diabetes Research and Clinical Practice 69 2005 129 135 (Pubitemid 40943477)
59. T. Vilsboll, and J.J. Holst Incretins, insulin secretion and type 2 diabetes mellitus Diabetologia 47 3 2004 357 366 (Pubitemid 38491230)
60. T. Vilsboll, T. Krarup, C.F. Deacon, S. Madsbad, and J.J. Holst Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients Diabetes 50 2001 609 613 (Pubitemid 32195226)
61. R. Wang, L. Lai, and S. Wang Further development and validation of empirical scoring functions for structure-based binding affinity prediction Journal of Computer-Aided Molecular Design 16 2002 11 26 (Pubitemid 34855041)
62. S. Wild, G. Roglic, A. Green, R. Sicree, and H. King Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 27 2004 1047 1053 (Pubitemid 38579764)
63. N. Yamagishi, K. Nakayama, T. Wakatsuki, and T. Hatayama Characteristic changes of stress protein expression in streptozotocin induced diabetic rats Life Sciences 9 2 2001 603 609
64. H. Zhang, J. Wei, R. Xue, J.D. Wu, W. Zhao, Z.Z. Wang, S.K. Wang, Z.X. Zhou, D.Q. Song, Y.M. Wang, H.N. Pan, W.J. Kong, and J.D. Jiang Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression Metabolism: Clinical and Experimental 59 2 2010 285 292
65. P. Zimmet, and C.R. Thomas Genotype, obesity and cardiovascular diseasehas technical and social advancement outstripped evolution Journal of Internal Medicine 254 2003 114 125 (Pubitemid 36900434)
66. T. Zerilli, and E.Y. Pyon Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus Clinical Therapeutics 29 2007 2614 2634